Developing traditional Chinese medicine in the era of evidence-based medicine: Current evidences and challenges

Evidence-based Complementary and Alternative Medicine

Volumn 2015, Issue , 2015, Pages

  Fung, Foon Yin ^a   Linn, Yeh Ching ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

HERBACEOUS AGENT; MAXINGSHIGAN YINQIAOSAN; NEUROAID; OSELTAMIVIR; TIANQI CAPSULE; UNCLASSIFIED DRUG;

ACUPUNCTURE; ADVERSE OUTCOME; ANALGESIA; ASIAN; CEREBROVASCULAR ACCIDENT; CHINESE MEDICINE; CHRONIC TENSION HEADACHE; CLINICAL EFFECTIVENESS; DRUG EFFICACY; DRUG GRANULE; DRUG SAFETY; EPISODIC CLUSTER HEADACHE; EVIDENCE BASED MEDICINE; FOLLOW UP; GOOD CLINICAL PRACTICE; HERB DRUG INTERACTION; HERBAL MEDICINE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; IN VITRO STUDY; INFLUENZA A (H1N1); IRRITABLE COLON; LONG TERM CARE; NONHUMAN; PAIN; PATIENT CARE; PHYSICIAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; SHORT COURSE THERAPY; WESTERN MEDICINE;

EID: 84928550082     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2015/425037     Document Type: Review

References (61)

1. D. L. Sackett, W. M. C. Rosenberg, J. A. M. Gray, R. B. Haynes, and W. S. Richardson, "Evidence based medicine: what it is and what it isn't, " British Medical Journal, vol. 312, no. 7023, pp. 71-72, 1996.
2. D. Melchart, K. Linde, W. Weidenhammer et al., "Use of traditional drugs in a hospital of Chinese medicine in Germany, " Pharmacoepidemiol Drug Safty, vol. 8, no. 2, pp. 115-120, 1999.
3. The Collaborative Centers for Integrative Medicine UCLA, 2014, http://cewm.med.ucla.edu/resources/ucla-ccim/.
4. National Center for Complementary and AlternativeMedicine, 2014, http://nccam.nih.gov/.
5. The National Institute of ComplementaryMedicine, University ofWestern Sydney, 2014, http://www.nicm.edu.au/.
6. Cleveland Clinic, Chinese Herbal Therapy, Cleveland Clinic, Cleveland, Ohio, USA, 2014, http://my.clevelandclinicorg/services/wellness/integrative-medicine/treatments-services/chinese-herbal-therapy.
7. WHO traditional medicine strategy: 2014-2023, http://www.who.int/medicines/publications/traditional/trm strategy1423/en/.
8. U. S. Phaemacopeial Convention Herbal Medicines Compendium, 2014, https://hmc.usp.org/monographs/all.
9. J. Ru, P. Li, J. Wang et al., "TCMSP: a database of systems pharmacology for drug discovery fromherbalmedicines, " Journal of Cheminformatics, vol. 6, no. 1, article 13, 2014.
10. Collaboration research group for Qinghaosu, "Antimalaria studies on Qinghaosu, " Chinese Medical Journal, vol. 92, no. 12, pp. 811-816, 1979.
11. A. Dondorp, F. Nosten, K. Stepniewska, N. Day, and N. White, "Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial, " The Lancet, vol. 366, no. 9487, pp. 717-725, 2005.
12. G. L. Sun, R. R. Ouyang, S. J. Chen et al., "Treatment of acute promyelocytic leukemia with all-trans retinoic acid. A five-year experience, " Chinese Medical Journal, vol. 106, no. 10, pp. 743-748, 1993.
13. S.-J. Chen, G.-B. Zhou, X.-W. Zhang, J.-H. Mao, H. deThé, and Z. Chen, "From an old remedy to a magic bullet: Molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia, " Blood, vol. 117, no. 24, pp. 6425-6437, 2011.
14. Z. Xu, "Modernization: one step at a time, " Nature, vol. 480, no. 7378, pp. S90-S92, 2011.
15. The Cochrane Collaboration, 2014, http://www.cochrane.org/.
16. G. Wang, B. Mao, Z.-Y. Xiong et al., "The quality of reporting of randomized controlled trials of traditional Chinesemedicine: a survey of 13 randomly selected journals from mainland China, " Clinical Therapeutics, vol. 29, no. 7, pp. 1456-1467, 2007.
17. J. Li, Z. Liu, R. Chen et al., "Thequality of reportsof randomized clinical trials on traditional Chinese medicine treatments: a systematic review of articles indexed in the China National Knowledge Infrastructure database from 2005 to 2012, " BMC Complementary and Alternative Medicine, vol. 14, article 362, 2014.
18. M. P. Farrell and S. Kummar, "Phase I/IIA randomized study of PHY906, a novel herbal agent, as a modulator of chemotherapy in patients with advanced colorectal cancer, " Clinical Colorectal Cancer, vol. 2, no. 4, pp. 253-256, 2003.
19. D. Luo, Researches on the productio and evaluation of the placebo of Chinese herbal granules [M. S. thesis], Chengdu University of Chinese Medicine, Chengdu, China, 2012.
20. J. L. Shea, "Applying evidence-based medicine to traditional Chinese medicine: debate and strategy, " Journal of Alternative and Complementary Medicine, vol. 12, no. 3, pp. 255-263, 2006.
21. C. Berle, D. Cobbin, N. Smith, and C. Zaslawski, "An innovative method to accommodate Chinese medicine pattern diagnosis within the framework of evidence-based medical research, " Chinese Journal of Integrative Medicine, vol. 17, no. 11, pp. 824-833, 2011.
22. Z.-X. Bian, D. Moher, Y.-P. Li et al., "Precise reporting of traditional Chinese medicine interventions in randomized controlled trials, " Journal of Chinese Integrative Medicine, vol. 6, no. 7, pp. 661-667, 2008.
23. Z. X. Bian, D. Moher, Y. P. Li et al., "Appropriately selecting and concisely reporting the outcome measures of randomized controlled trials of traditional Chinese medicine, " Zhong Xi Yi Jie He Xue Bao, vol. 6, no. 8, pp. 771-775, 2008.
24. Q. Xu, R. Bauer, B. M. Hendry et al., "The quest for modernisation of traditional Chinese medicine, " BMC Complementary and Alternative Medicine, vol. 13, article 132, 2013.
25. A. Bensoussan, N. J. Talley, M. Hing, R. Menzies, A. Guo, and M. Ngu, "Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial, " The Journal of the American Medical Association, vol. 280, no. 18, pp. 1585-1589, 1998.
26. C. Wang, B. Cao, Q.-Q. Liu et al., "Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial, " Annals of Internal Medicine, vol. 155, no. 4, pp. 217-226, 2011.
27. K. H. Kong, S. K. Wee, C. Y. Ng et al., "A double-blind, placebocontrolled, randomized phase II pilot study to investigate the potential efficacy of the traditional chinese medicine Neuroaid (MLC 601) in enhancing recovery after stroke (TIERS), " Cerebrovascular Diseases, vol. 28, no. 5, pp. 514-521, 2009.
28. F. J. Siddiqui, N. Venketasubramanian, E. S.-Y. Chan, and C. Chen, "Efficacy and safety ofMLC601 (NeuroAiD), a traditional chinese medicine, in poststroke recovery: a systematic review, " Cerebrovascular Diseases, vol. 35, supplement 1, pp. 8-17, 2013.
29. C. L. H. Chen, S. H. Y. Young, H. H. Gan et al., "Chinese medicine neuroaid efficacy on stroke recovery: a double-blind, placebo-controlled, randomized study, " Stroke, vol. 44, no. 8, pp. 2093-2100, 2013.
30. C. L. H. Chen, N. Venketasubramanian, C. F. Lee, K. S. L. Wong, M. G. Bousser, and CHIMES Study Investigators, "Effects of MLC601 on early vascular events in patients after stroke: the CHIMES study, " Stroke, vol. 44, no. 12, pp. 3580-3583, 2013.
31. Z. Chen, P. Sandercock, H. Pan et al., "Indications for early aspirin use in acute ischemic stroke: a combined analysis of 40 000 randomized patients from the Chinese Acute Stroke Trial and the International Stroke Trial. On behalf of the CAST and IST collaborative groups, " Stroke, vol. 31, no. 6, pp. 1240-1249, 2000.
32. N. Venketasubramanian, S. Young, S. S. Tay et al., "Chinese medicine NeuroAiD efficacy stroke recovery-extension study (CHIMES-E study): an observational multicenter study to investigate the longer-term efficacy of NeuroAiD in stroke recovery, " Cerebrovascular Diseases, vol. 35, supplement 1, pp. 18-22, 2013.
33. F. Lian, G. Li, X. Chen et al., "Chinese herbal medicine tianqi reduces progression from impaired glucose tolerance to diabetes: a double-blind, randomized, placebo-controlled, multicenter trial, " The Journal of Clinical Endocrinology and Metabolism, vol. 99, no. 2, pp. 648-655, 2014.
34. K. Linde, G. Allais, B. Brinkhaus, E. Manheimer, A. Vickers, and A. R. White, "Acupuncture for migraine prophylaxis, " The Cochrane Database of Systematic Reviews, no. 1, Article ID CD001218, 2009.
35. K. Linde, G. Allais, B. Brinkhaus, E. Manheimer, A. Vickers, and A. R. White, "Acupuncture for tension-type headache, " The Cochrane Database of Systematic Reviews, no. 1, Article ID CD007587, 2009.
36. K. V. Trinh, N. Graham, A. R. Gross et al., "Acupuncture for neck disorders, " The Cochrane Database of Systematic Reviews, no. 3, Article ID CD004870, 2006.
37. T. Manyanga, M. Froese, R. Zarychanski et al., "Pain management with acupuncture in osteoarthritis: a systematic review and meta-analysis, " BMC Complementary and Alternative Medicine, vol. 14, article 312, 2014.
38. J. Yan, V. F. Engle, Y. He, Y. Jiao, and W. Gu, "Study designs of randomized controlled trials not based on Chinese medicine theory are improper, " Chinese Medicine, vol. 4, article 3, 2009.
39. C.-W. Cheng, Z.-X. Bian, Y.-P. Li et al., "Transparently reporting adverse effects of traditional Chinesemedicine interventions in randomized controlled trials, " Zhong Xi Yi Jie He Xue Bao, vol. 6, no. 9, pp. 881-886, 2008.
40. G. M. Lord, R. Tagore, T. Cook, P. Gower, and C. D. Pusey, "Nephropathy caused by chinese herbs in the UK, " The Lancet, vol. 354, no. 9177, pp. 481-482, 1999.
41. S. L. Poon, S.-T. Pang, J. R. McPherson et al., "Genome-wide mutational signatures of aristolochic acid and its application as a screening tool, " Science Translational Medicine, vol. 5, no. 197, Article ID 197ra101, 2013.
42. T. Y. K. Chan, H. P. Tam, C. K. Lai, and A. Y. W. Chan, "A multidisciplinary approach to the toxicologic problems associated with the use of herbal medicines, "Therapeutic DrugMonitoring, vol. 27, no. 1, pp. 53-57, 2005.
43. S. P. L. Chen, S. W. Ng, W. T. Poon et al., "Aconite poisoning over 5 years: a case series in Hong Kong and lessons towards herbal safety, " Drug Safety, vol. 35, no. 7, pp. 575-587, 2012.
44. W. I. Lu and D. P. Lu, "Impact of chinese herbal medicine on american society and health care system: perspective and concern, " Evidence-Based Complementary and Alternative Medicine, vol. 2014, Article ID 251891, 2014.
45. R. A. Isbrucker and G. A. Burdock, "Risk and safety assessment on the consumption of Licorice root (Glycyrrhiza sp. ), its extract and powder as a food ingredient, with emphasis on the pharmacology and toxicology of glycyrrhizin, " Regulatory Toxicology and Pharmacology, vol. 46, no. 3, pp. 167-192, 2006.
46. M. M. Celik, A. Karakus, C. Zeren et al., "Licorice induced hypokalemia, edema, and thrombocytopenia, " Human and Experimental Toxicology, vol. 31, no. 12, pp. 1295-1298, 2012.
47. Y.-C. Linn, J. Lu, L.-C. Lim et al., "Berberine-induced haemolysis revisited: safety of Rhizoma coptidis and cortex phellodendri in chronic haematological diseases, " Phytotherapy Research, vol. 26, no. 5, pp. 682-686, 2012.
48. HSA Allows Chinese Proprietary Medicines Containing Berberine for Sale in Singapore from 1 January 2013, 2014, http://www.hsa.gov.sg/content/hsa/en/News Events/Press Releases/2012/hsa allows chinese.html.
49. S. Shi and U. Klotz, "Drug interactions with herbal medicines, " Clinical Pharmacokinetics, vol. 51, no. 2, pp. 77-104, 2012.
50. C. Gouws, D. Steyn, L. Du Plessis, J. Steenekamp, and J. H. Hamman, "Combination therapy of Western drugs and herbal medicines: recent advances in understanding interactions involving metabolism and efflux, " Expert Opinion on Drug Metabolism and Toxicology, vol. 8, no. 8, pp. 973-984, 2012.
51. L. G. Miller, "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions, " Archives of Internal Medicine, vol. 158, no. 20, pp. 2200-2211, 1998.
52. M. B. Izzat, A. P. C. Yim, and M. H. El-Zufari, "Ataste ofChinese medicine!, " Annals of Thoracic Surgery, vol. 66, no. 3, pp. 941-942, 1998.
53. C. M. Yu, J. C. N. Chan, and J. E. Sanderson, "Chinese herbs and warfarin potentiation by 'Danshen', " Journal of Internal Medicine, vol. 241, no. 4, pp. 337-339, 1997.
54. W. W. P. Wu and J. H. K. Yeung, "Inhibition of warfarin hydroxylation by major tanshinones of Danshen (Salvia miltiorrhiza) in the rat in vitro and in vivo, " Phytomedicine, vol. 17, no. 3-4, pp. 219-226, 2010.
55. Y. Wu, H. B. Guo, T. J. Wang, and Y. Y. Wang, "Comparative study on effects of active ingredients of several traditional Chinese medicines on rabbit platelet aggregation in vitro, " Chinese Journal of Clinical Pharmacology andTherapeutics, vol. 12, no. 9, pp. 1047-1051, 2007.
56. Q. Chang, S. Wo, K. L. K. Ngai et al., "Bench tobedevidences for pharmacokinetic and pharmacodynamic interactions involving oseltamivir and Chinese medicine, " Evidence-Based Complementary and Alternative Medicine, vol. 2014, Article ID 354172, 11 pages, 2014.
57. Onco-Informatics for Pharmaceutical Care, 2014, http://www.onco-informatics.com/.
58. H. Wang, X. Ye, Q. Gao et al., "Pharmacovigilance inTraditional Chinese Medicine safety surveillance, " Pharmacoepidemiology and Drug Safety, vol. 18, no. 5, pp. 357-361, 2009.
59. S.-C. Hsieh, J.-N. Lai, P.-C. Chen, H.-J. Chen, and J.-D. Wang, "Development of active safety surveillance system for traditional Chinesemedicine: an empirical study in treating climatic women, " Pharmacoepidemiology and Drug Safety, vol. 15, no. 12, pp. 889-899, 2006.
60. S.-K. Yee, S.-S. Chu, Y.-M. Xu, and P.-L. Choo, "Regulatory control of Chinese proprietary medicines in Singapore, " Health Policy, vol. 71, no. 2, pp. 133-149, 2005.
61. J.-L. Tang, "Research priorities in traditional Chinese medicine, " British Medical Journal, vol. 333, no. 7564, pp. 391-394, 2006.